Q3 2024 Earnings Call Transcript November 7, 2024 Operator: Thank you for standing by. My name is Kris and I will be your ...

Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) recently filed a Form 8-K with the Securities and Exchange Commission, detailing its financial performance for the third quarter of 2024. The company ...

Catalyst stock gains on strong third-quarter results, beating earnings and revenue estimates, primarily driven by Firdapse ...

Reports Q3 2024 Total Revenues of $128.7 Million, Representing a 25.3% YoY IncreaseRecord Revenues Driven by Continued Organic Growth in its Rare ...

For the quarter ended September 2024, Catalyst Pharmaceutical (CPRX) reported revenue of $128.7 million, up 25.3% over the same period last year. EPS came in at $0.57, compared to -$0.24 in the ...

Revising full-year 2024 net product revenue guidance for FIRDAPSE to be between $300 million and $310 million; reaffirming FYCOMPA net product revenue guidance to be between $130 million and $135 ...

Common side effects that may be seen with levetiracetam can include sleepiness and mood changes. Fycompa (perampanel) treats focal seizures with or without secondarily generalized seizures and primary ...

Eisai's epilepsy medication, Fycompa, was approved by the FDA in October of last year, however, the company is still waiting for the US Drug Enforcement Administration (DEA) to classify the drug ...